|1.||Vekilov, Peter G: 2 articles (12/2009 - 06/2002)|
|2.||Pan, Weichun: 1 article (12/2009)|
|3.||Uzunova, Veselina V: 1 article (12/2009)|
|4.||Girot, R: 1 article (01/2005)|
|5.||Girot, Robert: 1 article (01/2004)|
|6.||Bégué, Pierre: 1 article (01/2004)|
|7.||Park, Soobong: 1 article (03/2003)|
|8.||Venton, Duane L: 1 article (03/2003)|
|9.||Johnson, Michael E: 1 article (03/2003)|
|10.||Santarsiero, Bernard D: 1 article (03/2003)|
|1.||Sickle Cell Anemia (Hemoglobin S Disease)
07/01/1997 - "It has been shown recently that HbA2 is as potent as HbF in inhibiting intracellular deoxy-HbS polymerization, and its expression is therefore relevant to sickle cell disease treatment strategies. "
06/25/2002 - "In solutions of deoxy-HbS, we demonstrate that the dense liquid droplets facilitate the nucleation of HbS polymers, whose formation is the primary pathogenic event for sickle cell anemia. "
12/01/2009 - "We probe the role of free heme in the interactions between sickle cell hemoglobin (HbS) molecules in simulated physiological solutions: polymerization of deoxy-HbS is the primary pathogenic event of sickle cell anemia, and HbS releases heme after autoxidation more readily than normal adult hemoglobin. "
03/13/2003 - "The dual activities of increasing HbS oxygen affinity and directly inhibiting deoxy HbS polymerization, in conjunction with facile membrane traversal, suggest that these cationic isothiocyanates show substantial promise as lead compounds for development of therapeutic agents for sickle cell disease."